Carboplatin News and Research

RSS

Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers).

One dose chemo treatment the best for testicular cancer

New research from the UK has found that one dose of chemotherapy is the best way to cure testicular cancer in many patients.

6 Oct 2008

Benefits of combined treatments against cancer

In cancer therapy, the best results are often achieved by combining treatments such as chemotherapy, radiotherapy and surgery. This multidisciplinary approach is the focus of special symposia at the meetings of the European Society for Medical Oncology (ESMO) and the European Society for Therapeutic Radiology (ESTRO) taking place in Sweden this month.

16 Sep 2008

Single drug treatment a viable option to radiation for early testicular cancer

The results of research into early testicular cancer has found that a single chemotherapy treatment is just as effective as radiation therapy while much less toxic.

4 Jun 2008

Peregrine Pharmaceuticals updates on Bavituximab breast cancer study

Peregrine Pharmaceuticals, Inc. has announced that results from a Phase I clinical trial of its lead anti-phosphatidylserine (anti-PS) antibody bavituximab in combination with chemotherapy in patients with advanced cancer were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.

2 Jun 2008

First patient enrolled in phase III study of Bevacizumab and Trastuzumab in early breast cancer

A new international study for women with HER2-positive breast cancer is open for enrollment. The pivotal BETH (BEvacizumab and Trastuzumab Adjuvant Therapy in HER2-positive Breast Cancer) study is a Phase III clinical research trial that is investigating the benefits of combining two monoclonal antibodies, the anti-angiogenic, bevacizumab (Avastin) and the targeted therapy trastuzumab (Herceptin), together with chemotherapy for the treatment of patients with early stage HER2-positive breast cancer.

27 May 2008

Combining sorafenib with carboplatin/paclitaxel adds no benefit in lung cancer

A clinical trial evaluating the benefit of adding the drug sorafenib to the combination of carboplatin/paclitaxel chemotherapy for lung cancer patients has been stopped based on results from an interim analysis, after an independent data monitoring committee concluded that the study would not meet its primary endpoint of improved overall survival.

26 Apr 2008

Genentech updates on phase III study of Avastin plus chemo in first-line, advanced, non-squamous, non-small cell lung cancer

Genentech, Inc. has announced an update for the previously reported Roche-sponsored international Phase III clinical study (AVAiL) of Avastin (bevacizumab) in combination with gemcitabine and cisplatin chemotherapy, in patients with advanced, non-squamous, non-small cell lung cancer (NSCLC).

21 Apr 2008

High-dose chemo does not improve survival in small cell lung cancer

Small cell lung cancer (SCLC) patients treated with high-dose chemotherapy did not have better survival rates than those treated with standard doses, according to a randomized controlled trial published online April 8 in the Journal of the National Cancer Institute .

9 Apr 2008

Benefits of some cancer drugs exaggerated because trials were stopped early

Italian scientists say the benefits of some cancer drugs may be exaggerated as a rising number of trials are stopped early.

9 Apr 2008

Recurrent low-grade carcinoma of the ovary less responsive to chemo than more common ovarian cancers

Recurrent low-grade serous carcinoma, a rare type of ovarian cancer, is less sensitive to chemotherapy and therefore more difficult to treat than more common high-grade ovarian cancers, according to researchers from The University of Texas M. D. Anderson Cancer Center.

11 Mar 2008

Scientists discover why some breast cancers are drug resistant

Research by British scientists has revealed how cancer cells which have a faulty gene can become resistant to treatment.

13 Feb 2008

Cancer cells adapt using Darwin's 'survival of the fittest' principle to resist treatment

Scientists in London have discovered a new genetic mechanism which helps cancer cells survive by changing the way they respond to treatment.

11 Feb 2008

Avastin (bevacizumab) shows promise in phase II study of glioblastoma multiforme

Genentech, Inc. has announced that both study arms of a randomized, multi-center Phase II clinical study of Avastin (bevacizumab) administered alone or in combination with irinotecan chemotherapy demonstrated encouraging six-month progression-free survival (PFS) and objective response rate in patients with relapsed glioblastoma multiforme (GBM), the most common and aggressive type of brain cancer.

19 Nov 2007

New treatment option studied for bladder cancer

A chemotherapy regimen for patients with advanced bladder cancer who aren't eligible for standard treatment is under study at the Medical College of Georgia.

29 Oct 2007

Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma

Portal venous tumor thrombus (PVTT) is a crucial factor that can worsen the prognosis of patients with hepatocellular carcinoma (HCC).

18 Oct 2007

Taxotere (docetaxel) granted FDA approval to treat locally advanced head and neck cancer prior to chemo and surgery

Sanofi-aventis announced that the U.S. Food and Drug Administration (FDA) has approved Taxotere (docetaxel) Injection Concentrate in combination with cisplatin and 5-fluorouracil for induction therapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN) before patients undergo chemoradiotherapy and surgery.

2 Oct 2007

New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas

Childhood brainstem gliomas (BSGs) are rare but can be very difficult to treat successfully and they tend to have poor survival rates.

26 Sep 2007

Avastin approved in Europe for advanced lung cancer

Avastin (bevacizumab), Roche's innovative anti-cancer drug, was approved today in Europe for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), in combination with platinum-based chemotherapy.

26 Aug 2007

High-dose chemotherapy and a stem cell transplant cures testicular cancer

Testicular cancer patients who do not respond to traditional therapy can be cured with high-dose chemotherapy and a stem cell transplant, according to an Indiana University School of Medicine report in the July 26 issue of the New England Journal of Medicine.

26 Jul 2007

Study shows combination improves survival of metastatic melanoma patients

Two chemotherapy drugs combined with an agent that prevents the growth of blood vessels significantly delayed the spread of tumors in patients with metastatic melanoma, according to study findings presented at the 2007 American Association of Clinical Oncology (ASCO) Annual Meeting.

5 Jun 2007